(Boursier.com) — Innate Pharma reacted little on the 2.40 euros this Friday, when the group announced that its anti-KIR3DL2 antibody, lacutamab, had established clinical responses in patients with mycosis fungoides in the TELLOMAK Phase 2 trial. “We are delighted to see that lacutamab continues to demonstrate clinical activity in heavily pretreated patients with mycosis fungoides, supporting our hypothesis that this anti-KIR3DL2 antibody could provide clinical benefit to patients whose tumor expresses this target.” commented Joyson Karakunnel, Medical Director of Innate Pharma. “We look forward to sharing final data from the TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides in 2023 while advancing the two ongoing additional clinical trials with lacutamab in peripheral T-cell lymphoma.”
“Therapeutic options are limited for patients with advanced stages of mycosis fungoides and cutaneous T-cell lymphomas” added Prof. Martine Bagot, Head of the Dermatology Department at Saint Louis Hospital (Paris) and investigator in the TELLOMAK study. “In addition to the clinical responses observed and the favorable safety profile of lacutamab in the Phase 2 TELLOMAK study, the responses in the skin make lacutamab a very attractive treatment option for patients. We look forward to seeing the final results. of the study.”
Portzamparc speaks of “encouraging results” for lacutamab: “The activity seems relevant, but does not however allow any conclusion to be drawn as to the outcome of the study… Note that the final results are expected at the end of H1 2023 for lacutamab in MF. At this stage, we maintain our scenarios” concludes the analyst who remains buying on the file.
©2022 Boursier.com